Information date: 23 October 2026 — Imported medical devices must be registered with the National Medical Products Administration before sale in the mainland, with the registration route set by risk class. Class I devices follow filing, Class II and III follow registration, and the applicant must be a mainland legal entity — usually the foreign manufacturer's own subsidiary or a designated agent — that holds the registration certificate. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
Imported medical devices must be registered with the National Medical Products Administration before sale in the mainland, with the registration route set by risk class. Class I devices follow filing, Class II and III follow registration, and the applicant must be a mainland legal entity — usually the foreign manufacturer's own subsidiary or a designated agent — that holds the registration certificate.
Confirm the device's class under the mainland classification catalogue and any classification determination issued for comparable products; identify whether the product has a predicate already registered in the mainland; list the test items required, the availability of accredited test labs, and whether clinical evaluation can be satisfied by literature, equivalence to a predicate device, or requires a clinical trial.
How the effect reaches operations
Class assignment determines the reviewing authority, the dossier depth and the timeline: Class II and III applications go through technical review with type testing reports and a clinical evaluation report, and the clinical evaluation route depends on whether the device is novel, whether a same-variety predicate exists, and whether the equivalence argument can be supported by raw data rather than published literature alone.
Manufacturers commonly assume a CE mark or FDA clearance shortens the mainland route; it does not. Foreign test reports are generally not accepted in place of testing by a qualified mainland lab, and an equivalence argument to a predicate device can fail if the predicate's technical data is not accessible or if the differences affect safety and performance.
For “Guide: NMPA Medical Device Registration for Foreign Manufacturers — Class Determination, Type Testing and the Clinical Evaluation Exemption”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
If the device is novel or has no mainland predicate, plan for a clinical trial and budget accordingly. If a predicate exists and differences are minor, pursue the equivalence route and prepare a raw-data comparison rather than relying on published literature. Appoint the mainland legal applicant early, because the testing and dossier work depends on whose name the certificate will be held.
Implementation checklist
- Confirm the class and any predicate device before testing begins.
- Book accredited type testing early and align the model covered by the report.
- Draft the clinical evaluation report alongside the technical dossier.
- Assign one decision owner, one implementation owner and a dated review point for “Guide: NMPA Medical Device Registration for Foreign Manufacturers — Class Determination, Type Testing and the Clinical Evaluation Exemption”.
- For “Guide: NMPA Medical Device Registration for Foreign Manufacturers — Class Determination, Type Testing and the Clinical Evaluation Exemption”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “Guide: NMPA Medical Device Registration for Foreign Manufacturers — Class Determination, Type Testing and the Clinical Evaluation Exemption”.
Evidence and review
For “Guide: NMPA Medical Device Registration for Foreign Manufacturers — Class Determination, Type Testing and the Clinical Evaluation Exemption”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Confirm the class and any predicate device before testing begins.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Book accredited type testing early and align the model covered by the report.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Draft the clinical evaluation report alongside the technical dossier.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
This summarises public regulatory requirements and does not constitute regulatory, clinical or legal advice; the applicable pathway must be confirmed with NMPA and qualified local counsel.
